Peutz-Jeghers syndrome and screening for pancreatic cancer

British Journal of Surgery

Volumn 93, Issue 12, 2006, Pages 1446-1455

  Latchford, A ^a   Greenhalf, W ^b   Vitone, L J ^b   Neoptolemos, J P ^b   Lancaster, G A ^b   Phillips, R K S ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ACUTE PANCREATITIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE MUTATION; GENETIC LINKAGE; HUMAN; MEDICAL SOCIETY; META ANALYSIS; PANCREAS CANCER; PANCREAS RESECTION; PANCREATITIS; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ADULT; AGED; COST-BENEFIT ANALYSIS; FALSE POSITIVE REACTIONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; MIDDLE AGED; PANCREATIC NEOPLASMS; PEUTZ-JEGHERS SYNDROME; RISK FACTORS;

EID: 33845461150     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5609     Document Type: Review

References (92)

1. Peutz JL. Very remarkable case of familial polyposis of mucous membrane of intestinal tract and nasopharynx accompanied by peculiar pigmentation of skin and mucous membrane. Nederl Maandisch Geneeskd 1921; 10: 134-146.
2. Jeghers H. Pigmentation of the skin. N Engl J Med 1944; 231: 88-100.
3. Mallory SB, Stough DB IV. Genodermatoses with malignant potential. Dermatol Clin 1987; 5: 221-230.
4. Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci 1999; 55: 735-750.
5. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987; 316: 1511-1514.
6. Tomlinson IP, Houlston RS. Peutz-Jeghers syndrome. J Med Genet 1997; 34: 1007-1011.
7. Westerman AM, Entius MM, de Baar E, Boor PP, Koole R, van Velthuysen ML et al. Peutz-Jeghers syndrome: 78-year follow-up of the original family. Lancet 1999; 353: 1211-1215.
8. Wada K, Tanaka M, Yamaguchi K, Wada K. Carcinoma and polyps of the gallbladder associated with Peutz-Jeghers syndrome. Dig Dis Sci 1987; 32: 943-946.
9. Hemminki A, Tomlinson I, Markie D, Jarvinen H, Sistonen P, Bjorkqvist AM et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997; 15: 87-90.
10. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-187.
11. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18: 38-43.
12. Boudeau J, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 2003; 546: 159-165.
13. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-2008.
14. Forcet C, Etienne-Manneville S, Gaude H, Fournier L, Debilly S, Salmi M et al. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum Mol Genet 2005; 14: 1283-1292.
15. Ossipova O, Bardeesy N, DePinho RA, Green JB. LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat Cell Biol 2003; 5: 889-894.
16. Lin-Marq N, Borel C, Antonarakis SE. Peutz-Jeghers LKB1 mutants fail to activate GSK-3beta, preventing it from inhibiting Wnt signaling. Mol Genet Genomics 2005; 273: 184-196.
17. Mehenni H, Lin-Marq N, Buchet-Poyau K, Reymond A, Collart MA, Picard D et al. LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet 2005; 14: 2209-2219.
18. Lim W, Hearle N, Shah B, Murday V, Hodgson SV, Lucassen A et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 2003; 89: 308-313.
19. Yoon KA, Ku JL, Choi HS, Heo SC, Jeong SY, Park YJ et al. Germline mutations of the STK11 gene in Korean Peutz-Jeghers syndrome patients. Br J Cancer 2000; 82: 1403-1406.
20. Wang ZJ, Churchman M, Avizienyte E, McKeown C, Davies S, Evans DG et al. Germline mutations of the LKB1 (STK11) gene in Peutz-Jeghers patients. J Med Genet 1999; 36: 365-368.
21. Mehenni H, Gehrig C, Nezu J, Oku A, Shimane M, Rossier C et al. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 1998; 63: 1641-1650.
22. Olschwang S, Boisson C, Thomas G. Peutz-Jeghers families unlinked to STK11/LKB1 gene mutations are highly predisposed to primitive biliary adenocarcinoma. J Med Genet 2001; 38: 356-360.
23. Lim W, Olschwang S, Keller JJ, Westerman AM, Menko FH, Boardman LA et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004; 126: 1788-1794.
24. Burdick D, Prior JT. Peutz-Jeghers syndrome. A clinicopathologic study of a large family with a 2 7-year follow-up. Cancer 1982; 50: 2139-2146.
25. Foley TR, McGarrity TJ, Abt AB. Peutz-Jeghers syndrome: a clinicopathologic survey of the 'Harrisburg family' with a 49-year follow-up. Gastroenterology 1988; 95: 1535-1540.
26. Spigelman AD, Murday V, Phillips RK. Cancer and the Peutz-Jeghers syndrome. Gut 1989; 30: 1588-1590.
27. Boardman LA, Thibodeau SN, Schaid DJ, Lindor NM, McDonnell SK, Burgart LJ et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128: 896-899.
28. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453.
29. Utsunomiya J, Nakamura T. The occult osteomatous changes in the mandible in patients with familial polyposis coli. Br J Surg 1975; 62: 45-51.
30. Linos DA, Dozois RR, Dahlin DC, Bartholomew LG. Does Peutz-Jeghers syndrome predispose to gastrointestinal malignancy? A later look. Arch Surg 1981; 116: 1182-1184.
31. Hizawa K, Iida M, Matsumoto T, Kohrogi N, Kinoshita H, Yao T et al. Cancer in Peutz-Jeghers syndrome. Cancer 1993; 72: 2777-2781.
32. Chang B, Borer JG, Tan PE, Diamond DA. Large-cell calcifying Sertoli cell tumor of the testis: case report and review of the literature. Urology 1998; 52: 520-522; discussion 522-523.
33. Yu C, Zelterman D. Statistical inference for familial disease clusters. Biometrics 2002; 58: 481-491.
34. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl 8): 4-66.
35. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003; 14: 675-692.
36. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
37. Martin SP, Ulrich CD II. Pancreatic cancer surveillance in a high-risk cohort - is it worth the cost? Med Clin North Am 2000; 84: 739-747.
38. Ellis I, Lerch MM, Whitcomb DC. Genetic testing for hereditary pancreatitis: guidelines for indications, counselling, consent and privacy issues. Pancreatology 2001; 1: 405-415.
39. Ulrich CD. Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology 2001; 1: 416-422.
40. Whitcomb DC, Ulrich CD, Lerch MM, Durie P, Neoptolemos JP, Maisonneuve P et al. Third International Symposium on Inherited Diseases of the Pancreas. Pancreatology 2001; 1: 423-431.
41. Wong T, Howes N, Threadgold J, Smart H, Lombard M, Gilmore I et al. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 2001; 1: 486-509.
42. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003; 27: 87-93.
43. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437.
44. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2: 252-261.
45. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998; 7: 67-91.
46. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002; 51: 849-852.
47. Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002; 23: 133-149.
48. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95: 214-221.
49. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am 2000; 84: 707-718.
50. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830-1837.
51. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ et al. Familial pancreatic cancer: a review. Semin Oncol 1996; 23: 251-275.
52. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko F, Brune KA, Goggins M et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7: 738-744.
53. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000; 11: 915-923.
54. Bartsch DK. Familial pancreatic cancer. Br J Surg 2003; 90: 386-387.
55. Malats N, Casals T, Porta M, Guarner L, Estivill X, Real FX. Cystic fibrosis transmembrane regulator (CFTR) DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group. Gut 2001; 48: 70-74.
56. Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154: 1835-1840.
57. Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990; 61: 932-936.
58. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993; 104: 1535-1549.
59. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994; 8: 392-398.
60. Ishikawa O, Ohigashi H, Imaoka S, Nakaizumi A, Uehara H, Kitamura T et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter - collective review of Japanese case reports. Hepatogastroenterology 1999; 46: 8-15.
61. Tsuchiya R, Tajima Y, Matsuzaki S, Onizuka S, Kanematsu T. Early pancreatic cancer. Pancreatology 2001; 1: 597-603.
62. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156: 1821-1825.
63. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
64. Biankin AV, Kench JG, Dijkman FP, Biankin SA, Henshall SM. Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 2003; 35: 14-24.
65. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998; 22: 163-169.
66. Brockie E, Anand A, Albores-Saavedra J. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann Diagn Pathol 1998; 2: 286-292.
67. Manabe T, Miyashita T, Ohshio G, Nonaka A, Suzuki T, Endo K et al. Small carcinoma of the pancreas. Clinical and pathologic evaluation of 17 patients. Cancer 1988; 62: 135-141.
68. Hayakawa T, Kondo T, Shibata T, Hamano H, Kitagawa M, Sakai Y et al. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988; 61: 1827-1831.
69. Graham RA, Bankoff M, Hediger R, Shaker HZ, Reinhold RB. Fine-needle aspiration biopsy of pancreatic ductal adenocarcinoma: loss of diagnostic accuracy with small tumors. J Surg Oncol 1994; 55: 92-94.
70. Saisho H, Yamaguchi T. Diagnostic imaging for pancreatic cancer: computed tomography, magnetic resonance imaging, and positron emission tomography. Pancreas 2004; 28: 273-278.
71. Maluf-Filho F, Sakai P, Cunha JE, Garrido T, Rocha M, Machado MC et al. Radial endoscopic ultrasound and spiral computed tomography in the diagnosis and staging of periampullary tumors. Pancreatology 2004; 4: 122-128.
72. Akahoshi K, Chijiiwa Y, Nakano I, Nawata H, Ogawa Y, Tanaka M et al. Diagnosis and staging of pancreatic cancer by endoscopic ultrasound. Br J Radiol 1998; 71: 492-496.
73. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999; 131: 247-255.
74. Klump B, Hsieh CJ, Nehls O, Dette S, Holzmann K, Kiesslich R et al. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer 2003; 88: 217-222.
75. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001; 1: 477-485.
76. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
77. Howes N, Greenhalf W, Neoptolemos J. Screening for early pancreatic ductal adenocarcinoma in hereditary pancreatitis. Med Clin North Am 2000; 84: 719-738.
78. Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005; 128: 2124-2130.
79. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
80. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130.
81. Fukushima N, Walter KM, Uek T, Sato N, Matsubayashi H, Cameron JL et al. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2003; 2: 78-83.
82. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, Brune K et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 2003; 9: 1446-1452.
83. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734.
84. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998; 16: 3158-3168.
85. Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T et al. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res 1999; 5: 1147-1153.
86. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK JR, Perrault J et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89: 442-446.
87. Lynch H, Brand R, Lynch J, Fusaro R, Kern S. Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 12-31.
88. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316.
89. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621.
90. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434.
91. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003; 57: 23-29.
92. Choi HS, Park YJ, Youk EG, Yoon KA, Ku JL, Kim NK et al. Clinical characteristics of Peutz-Jeghers syndrome in Korean polyposis patients. Int J Colorectal Dis 2000; 15: 35-38.